Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection  by Huang, Chung-Feng et al.
Kaohsiung Journal of Medical Sciences (2015) 31, 271e277Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.kjms-onl ine.comORIGINAL ARTICLEHost and virological characteristics of patients
with hepatitis C virus mixed genotype 1 and 2
infection
Chung-Feng Huang a,b, Ching-I Huang a,c, Ming-Lun Yeh c, Jee-Fu Huang c,d,
Ming-Yen Hsieh c, Zu-Yau Lin c,d, Shinn-Cherng Chen c,d, Ming-Lung Yu c,d,
Chia-Yen Dai c,d,e,f,*, Wan-Long Chuang c,da Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University,
Kaohsiung, Taiwan
b Department of Occupational Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung
Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
c Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University
Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
d Faculty of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical
University, Kaohsiung, Taiwan
e Department of Occupational Medicine, Kaohsiung Medical University Hospital,
Kaohsiung Medical University, Kaohsiung, Taiwan
f Department of Preventive Medicine, Kaohsiung Medical University Hospital,
Kaohsiung Medical University, Kaohsiung, TaiwanReceived 3 July 2014; accepted 6 February 2015
Available online 12 March 2015KEYWORDS
Genotype;
Hepatitis C virus;
Interleukin-28B;
Mixed infectionConflicts of interest: All authors d
* Corresponding author. Hepatobilia
1st Road, Kaohsiung 807, Taiwan.
E-mail addresses: daichiayen@gma
http://dx.doi.org/10.1016/j.kjms.201
1607-551X/Copyright ª 2015, KaohsiuAbstract The prevalence and characteristics of patients with hepatitis C virus mixed geno-
type 1 and 2 infection (HCV-1/2) remains unclear. For each HCV-1/2 patient with histological
data available, two age- and sex-matched HCV-1 and HCV-2 infected patients were selected
for comparison, respectively. Of the 2776 patients, 261 (9.4%) patients were identified as hav-
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272 C.-F. Huang et al.higher than that of HCV-2 infection (5.1  0.9 log IU/mL, both p < 0.001). Linear regression
analysis revealed that the factors of HCV-1/2 infection [b: 0.204; 95% confidence interval
(CI): 0.183e0.598, p < 0.001], body weight (b: 0.150; CI: 0.003e0.021, p Z 0.008), and age
(b: 0.139; CI: 0.020 to 0.002, p Z 0.01) were independently correlated with HCV RNA
levels in patients with HCV-2 and mixed HCV-1/2 infection. We concluded that the host genetic
and viral presentations of patients with mixed HCV-1/2 infection were more similar to those of
patients with HCV-1 infection than patients with HCV-2 infection.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Hepatitis C virus (HCV) infection is a major health issue that
affects an estimated 170 million people worldwide [1,2]. An
increased incidence of HCV-related end-stage liver disease
and hepatocellular carcinoma has been noted in the past
decade [3,4]. There are six HCV genotypes and more than
50 subtypes, which tend to segregate geographically.
Regional distributions of HCV genotypes are diverse,
reflecting the variability of acquisition routes and ethnic
differences. HCV genotypes 1 (HCV-1), 2, and 3 have a fairly
broad geographical distribution, whereas HCV genotypes 4,
5, and 6 are generally restricted to specific regions [5,6].
The understanding of viral genotype not only facilitates
HCV treatment on an individualized basis [6e8] but also
helps to elucidate the pathological nature of HCV infection
[9]. For example, patients with HCV-1 infection have a
lower sustained response (SVR) rate than patients with
HCV-2. HCV-1b has been shown to have a higher risk for
developing into hepatocellular carcinoma compared to
other viral genotypes [9].
However, interleukin 28B (IL-28B) genetic variants have
been recognized as the most important host factor either in
the treatment of HCV infection [10e14] or in the influence of
spontaneous HCV clearance [15]. We have demonstrated that
viral genotype differences regarding IL-28B genotype distri-
bution exist, which might in part be responsible for different
treatment responses between HCV-1 and HCV-2 [16].
We have recently demonstrated that the treatment ef-
ficacy of patients with mixed HCV-1 and HCV-2 infection
(HCV-1/2) was satisfactory in Asian patients receiving
pegylated interferon/ribavirin combination therapy [17].
However, the prevalence of patients with mixed HCV-1/2
infection is unclear, and the clinical presentation, in
terms of viral and host characteristics, such as IL-28B ge-
netic variants, remains elusive. Taiwan possesses a unique
epidemiological background because HCV is widely endemic
and both HCV-1 and HCV-2 prevail throughout the entire
country [6,18,19]. It is essential to fully clarify the host and
virological characteristics of this population before the
treatment strategy can be recommended. We herein
retrospectively analyzed a hospital-based cohort with a
respectable sample size to address this issue.
Materials and methods
Eligible individuals were treatment-naı¨ve chronic hepatitis
C patients that were enrolled consecutively in a medicalcenter and two core regional hospitals in southern Taiwan
from 2001 to 2011. First, we analyzed the prevalence and
characteristics of all the patients with mixed HCV-1/2
infection in the hospital cohort. To clarify the differences
between mixed infections and other viral genotypes, pa-
tients with mixed HCV-1/2 infection with available histo-
logical data were selected to compare with age- and sex-
matched HCV-1 and HCV-2 controls. All of the patients
provided written informed consent prior to enrollment.
Anti-HCV antibodies were detected using a third-
generation, commercially available enzyme-linked immu-
nosorbent assay kit (AxSYM 3.0; Abbott Laboratories, Chi-
cago, IL, USA). Serum HCV RNA was obtained using real-
time polymerase chain reaction (COBAS AMPLICOR Hepatitis
C Virus Test, ver. 2.0; Roche, Branchburg, NJ, USA; detec-
tion limit: 50 IU/mL). HCV genotypes were determined
using the Okamoto method [20]. Liver histology was graded
and staged according to the scoring system described by
Knodell and Scheuer [21]. Biochemical items were
measured on a multichannel auto analyzer (Hitachi Inc.,
Tokyo, Japan). The IL-28B genotypes of the patients were
determined by the ABI TaqMan single nucleotide poly-
morphism (SNP) genotyping assays (Applied Biosystems,
Foster City, CA, USA) using the predesigned commercial
genotyping assays (ABI Assay ID: C__11710096_10). Briefly,
polymerase chain reaction (PCR) primers and two allele-
specific probes were designed to detect the specific SNP
target. The PCR reactions were performed in 96-well
microplates using ABI 7500 real-time PCR (Applied Bio-
systems). Allele discrimination was achieved by detecting
fluorescence using ABI System SDS software version 1.2.3
(Applied Biosystems). The institutional review board at
Kaohsiung Medical University Hospital approved the proto-
col, which conformed to the guidelines of the International
Conference on Harmonization for Good Clinical Practice.Statistical analyses
IL-28B rs8099917 was selected as the candidate SNP analysis
in the current study based on findings in our previous
studies [10,11,22]. The frequency was compared between
groups using the c2 test, with the Yates correction or
Fisher’s exact test. Group means, presented as the mean
values and standard deviation, were compared using anal-
ysis of variance and the Student t test or the Man-
neWhitney U test. Serum HCV RNA levels were expressed
after logarithmic transformation of original values. To
represent the severity of liver fibrosis, the aspartate
Table 1 Basic demographic and clinical features of the
261 patients with mixed HCV-1 and HCV-2 infection.
Sex, n (%)
Male 155 (59.4)
Female 106 (40.6)
Age (y), mean  SD 51.0  11.9
Body weight (kg), mean  SD 67.4  12.9
Rs8099917 TT genotype, n/N (%)a 154/184 (83.7)
Baseline HCV RNA (log IU/mL), mean  SD 5.7  0.9
Baseline viral loads > 400,000 IU/mL, n (%) 157 (60.2)
Fibrosis, n (%)
0e2 76 (73.1)
3e4 28 (26.9)
HAI, mean  SD 5.1  2.7
AST (IU/L), mean  SD 94.4  68.0
ALT (IU/L), mean  SD 144.3  154.8
GGT (IU/L), mean  SD 76.4  78.5
APRI, mean  SD 2.6  2.1
Fasting sugar (mg/dL), mean  SD 102.1  34.8
Genotype distribution, n (%)
1aþ 2a 2 (0.8)
1b þ 2a 117 (44.8)
1b þ 2b 114 (43.7)
1aþ 2a þ 2b 26 (10.0)
1aþ 1b þ 2a þ 2b 1 (0.4)
1aþ 1b þ 2a 1 (0.4)
ALT Z aspartate aminotransferase; APRI Z alanine amino-
transferase to platelet ratio index; AST Z alanine aminotrans-
ferase; GGTZ gamma-glutamyl transferase; HAIZ histological
activity index; HCV Z hepatitis C virus; SD Z standard
deviation.
a Data available in 184 patients.
HCV mixed infection 273aminotransferase (AST)-to-platelet ratio index (APRI) was
calculated using the following equation: (AST level/upper
limit of normal range)/platelet counts (109/L)  100
[23,24]. The frequencies of the rare allele of the rs8099917
genotype were too low; thus, the rare homozygote and
heterozygote were combined together while analyzing the
SNP. Logistic regression and linear regression analysis were
performed to evaluate the independent factors associated
with HCV RNA levels. The statistical analyses were per-
formed using the SPSS 12.0 statistical package (SPSS, Chi-
cago, IL, USA). All statistical analyses were based on two-
tailed hypothesis tests with a significance level of p < 0.05.
Results
Overall patient characteristics in the hospital-
based cohort
Of the 2776 patients, 311 (11.2%) were identified with HCV
mixed infection and 261 (9.4%) were identified with mixed
HCV-1/2 infections (Fig. 1). The basic demographic, virolog-
ical, and clinical features of the 261 patients are shown in
Table 1. The mean age was 51.0  11.9 years. Males
accounted for 59.4% of the population. The mean HCV RNA
levels were 5.7 0.9 log IU/mL. Among the 184 patients with
available IL-28B genotype information, the rs8099917 TT ge-
notype accounted for 154 (83.7%) patients, and 30 (16.3%)
patients had the rs8099917 non-TT genotype. Themajority of
mixed HCV infections in patients were of the 1b/2a genotype
(44.8%), followed by the 1b/2b genotype (43.7%). The clinical
presentations between the two subpopulations were iden-
tical except that patients with HCV-1b/2b infection were
younger and had higher HCV RNA levels (Table S2).
Characteristics of mixed HCV-1/2 infection in
comparison with other HCV genotypes
A total of 104 patients had histological data available. The
characteristics did not differ between the patients with or
without available histology data except that patients with2776 treatment-naïve C
Pure HCV-1
(n = 1294, 46.6%)
Pure HCV-2
(n = 1162, 41.9% )
Histology available 
(n = 104)
208 age-, sex-matched 
HCV-1 and HCV-2 
controls, respectively
Figure 1. Distribution of HCV genotypes in the cohort.unavailable data were older and had lower AST levels
(Table S1). To fully explore the characteristics of patients
with mixed HCV-1/2 infection, patients that were age- and
sex-matched and infected with either HCV-1 or HCV-2 were
selected for comparison with 1:2 ratios (Fig. 1). As shown in
Table 2, the histological severity in terms of liver fibrosis
and histological activity index did not differ among patientsHC patients
Other genotypes
(n = 9, 0.3%)
Mixed HCV genotypes
(n = 311, 11.2%)
Mixed other genotypes
(n = 50,1.8%)
Histology 
unavailable
(n = 157)
CHC Z chronic hepatitis C; HCV Z hepatitis C virus.
Table 2 Basic demographic and clinical features of the three patient groups with different HCV genotypes.
Mixed HCV-1/2
(n Z 104)
HCV-1
(n Z 208)
HCV-2
(n Z 208)
p
Sex, n (%) 0.94
Male 64 (61.5) 125 (60.1) 128 (61.5)
Female 40 (38.5) 83 (39.9) 80 (38.5)
Age (y), mean  SD 48.8  12.1 48.5  11.4 47.9  10.8 0.78
Body weight (kg), mean  SD 66.3  11.8 65.8  10.2 65.5  11.3 0.82
Rs8099917 TT genotype, n/N (%) a 71/86 (82.6) * 180/208 (86.5) 174/190 (91.6) * 0.08
Fibrosis, n (%) 0.31
0e2 76 (73.1) 152 (73.4) 160 (77.7)
3e4 28 (26.9) 55 (26.6) 46 (22.3)
HAI, mean  SD 5.1  2.7 4.8  2.6 5.0  2.7 0.7
Baseline HCV RNA
(log IU/mL), mean  SD
5.5  0.8 ** 5.5  0.9 ** 5.1  1.0 ** < 0.001 **
AST (IU/L), mean  SD 105.1  64.6 97.8  59.3 103.2  65.6 0.54
ALT (IU/L), mean  SD 158.6  109.5 149.8  87.9 167.0  110.3 0.23
GGT (IU/L), mean  SD 77.2  70.6 60.9  50.6 65.9  57.8 0.07
APRI, mean  SD 2.9  2.2 2.7  2.0 2.9  2.5 0.51
Fasting sugar (mg/dL), mean  SD 105.8  46.0 100.9  26.3 102.8  39.2 0.54
* p Z 0.03; ** p < 0.001.
ALT Z aspartate aminotransferase; APRI Z alanine aminotransferase to platelet ratio index; AST Z alanine aminotransferase;
GGT Z gamma-glutamyl transferase; HAI Z histological activity index; HCV Z hepatitis C virus; mixed HCV-1/2 genotype Z HCV ge-
notype 1 and HCV genotype 2 mixed infection; SD Z standard deviation.
a Data available in 484 patients.
274 C.-F. Huang et al.with mixed HCV-1/2, HCV-1, and HCV-2 infection. The
proportion of the IL-28B rs8099917 TT genotype did not
differ between patients with mixed-1/2 and HCV-1 infec-
tion (82.6% vs. 86.5%, p Z 0.38). However, HCV-2 infected
patients had a significantly higher proportion of the
rs8099917 TT genotype compared to patients with mixed
HCV-1/2 infection (91.6% vs. 82.6%, p Z 0.03). The HCV
RNA levels were similar between patients with HCV-1/2 andTable 3 Factors associated with high or low viral loads among
High viral loads
(n Z 130)
Low vira
(n Z
Male sex, n (%) 86 (66.2) 106 (58.
Age (y), mean  SD 46.5  12.8 49.5  9
Rs8099917 TT genotype, n/N (%) b 99/115 (86.1) 146/161
Fibrosis 3/4, n/N (%) 31/130 (23.8) 43/180 (
HAI, mean  SD 5.1  2.8 4.8  2.
Body weight (kg), mean  SD 68.1  11.4 64.1  1
AST (IU/L), mean  SD 100.0  64.8 106.6 
ALT (IU/L), mean  SD 165.4  119.4 163.3 
GGT (IU/L), mean  SD 72.1  59.8 67.8  6
APRI, mean  SD 2.6  2.2 3.1  2.
Fasting sugar (mg/dL), mean  SD 103.7  31.8 103.9 
HCV genotype, n (%)
HCV-2 73 (56.2) 135 (74.
Mixed HCV-1/2 57 (43.8) 47 (25.8
ALT Z aspartate aminotransferase; APRI Z alanine aminotransfer
CIZ confidence interval; GGTZ gamma-glutamyl transferase; HAIZ
2 Z HCV genotype 1 and HCV genotype 2 mixed infection; OR Z odd
a High viral loads defined as HCV RNA > 400,000 IU/Ml.
b Data available in 276 patients.HCV-1 infection (5.5  0.8 log IU/mL vs. 5.5  0.9 log IU/L,
pZ 0.73), which were both significantly higher than that of
HCV-2 infection (5.1  0.9 log IU/mL, both p < 0.001).
The HCV RNA levels were so similar between patients
with mixed HCV-1/2 and HCV-1 infection that we further
analyzed the characteristics associated with HCV RNA
levels among patients with HCV-2 and mixed HCV-1/2
infection. As shown in Table 3, younger age, higher bodypatients with HCV-2 and mixed HCV-1/2 infection. a
l loads
182)
p Logistic regression analysis of factors
associated with high viral loads
OR 95% CI p
2) 0.16
.9 0.03 0.979 0.958e1.000 0.05
(90.7) 0.23
26.4) 0.99
6 0.12
1.1 0.002 1.030 1.008e1.052 0.007
65.5 0.38
103.0 0.87
4.4 0.55
5 0.06
47.6 0.96
0.001 2.171 1.324e3.559 0.002
2)
)
ase to platelet ratio index; AST Z alanine aminotransferase;
histological activity index; HCVZ hepatitis C virus; mixed HCV-1/
s ratio; SD Z standard deviation.
Table 4 Linear regression analysis of factors associated
with viral loads among patients with HCV-2 and mixed HCV-
1/2 infection. a
b Standard
error
95% CI for b b p
Body
weight
0.012 0.004 0.003 0.021 0.150 0.008
Mixed
HCV-1/2
genotype
0.391 0.105 0.183 0.598 0.204 < 0.001
Age 0.011 0.004 0.020 0.002 0.139 0.01
CI Z confidence interval; HCV Z hepatitis C virus; mixed HCV-
1/2 genotype Z HCV genotype 1 and HCV genotype 2 mixed
infection.
a Odds ratios (ORs) are for body weight (per 1 kg increase),
age (per 1 year increase), and HCV genotype (mixed HCV ge-
notype 1and 2 vs. HCV genotype 2).
HCV mixed infection 275weight, and mixed HCV-1/2 infection were factors associ-
ated with high viral loads, defined as HCV RNA levels >
400,000 IU/mL, in univariate analysis. Multivariate analysis
revealed that the strongest factor associated with high viral
loads was mixed HCV-1/2 infection [odds ratio (OR)/95%
confidence interval (CI): 2.171/1.324e3.559, p Z 0.002]
followed by body weight (OR/CI: 1.030/1.008e1.052,
pZ 0.007), and age (OR/CI: 0.979/0.958e1.000, pZ 0.05).
Linear regression analysis revealed that the factors of HCV-
1/2 infection (b: 0.204; 95% CI: 0.183e0.598, p < 0.001),
body weight (b: 0.150; 95% CI: 0.003e0.021, pZ 0.008) and
age (b: 0.139; 95% CI: 0.020e0.002, p Z 0.01) were
independently correlated with HCV RNA levels (Table 4).The interplay of HCV RNA levels and host IL-28B
genotype
As shown in Table 5, the HCV RNA levels did not differ be-
tween HCV-1 patients with the rs8099917 TT genotype and
the rs8099917 non-TT genotype (5.49  0.94 log IU/mL vs.
5.51  0.70 log IU/mL, p Z 0.92). The HCV RNA levels also
did not differ between mixed HCV-1/2 patients with the
rs8099917 TT genotype and the rs8099917 non-TT genotype
(5.60  0.83 log IU/mL vs. 5.55  0.74 log IU/mL,
p Z 0.92). However, the HCV RNA levels were significantly
lower in HCV-2 patients with the rs8099917 TT genotype
compared with those with the rs8099917 non-TT genotype
(5.07  0.95 log IU/mL vs. 5.57  0.54 log IU/mL,Table 5 HCV RNA levels in different HCV genotypes stratified b
Rs809991
HCV-1 and mixed HCV-1/2 (log IU/mL), mean (SD) 5.5
Mixed HCV-1/2 (log IU/mL), mean (SD) 5.6
HCV-1 (log IU/mL), mean (SD) 5.4
HCV-2 (log IU/mL), mean (SD) 4.9
* p < 0.001.
HCV Z hepatitis C virus; IL-28B Z interleukin 28B; mixed HCV-1
SD Z standard deviation.pZ 0.003). The difference in HCV RNA levels between HCV-
2 and other HCV genotypes existed only in patients with the
rs8099917 TT genotype (p < 0.001) but not in those with the
rs8099917 non-TT genotype (Table 5). Among patients with
the rs8099917 TT genotype, patients with mixed HCV-1/2
infection had a significantly higher proportion of high viral
loads compared to patients with HCV-2 infection (59.2% vs.
33.9%, p < 0.001), and the proportion of high viral loads did
not differ between non-TT genotype carriers with HCV-2
and mixed HCV-1/2 infection (53.3% vs. 50.0%, p Z 1)
(Fig. 2).Discussion
To our knowledge, this is the first study to address the
prevalence and characteristics of patients with mixed in-
fections with HCV-1 and HCV-2. We demonstrated that one
out of 10 HCV patients was infected with mixed HCV-1/2 in
Taiwan. The liver disease severity, in terms of necroin-
flammation and fibrosis, was similar between the study
population and those infected with other viral genotypes.
Nevertheless, the host IL-28B genetic predisposition and
viral presentation of patients with mixed HCV-1/2 infection
were more similar to those with HCV-1 infection. Compared
with patients with HCV-2 infection, patients with mixed
HCV-1/2 infection had a significantly lower proportion of
favorable IL-28B genotype carriage and higher HCV RNA
levels.
Superinfection of heterologous HCV in the same host was
first demonstrated in chimpanzees [25,26]. Presentation as
acute hepatitis in humans was reported shortly thereafter
in early 1990 [27] and was further confirmed in a subse-
quent case-series study [28]. The definition of mixed HCV
genotype infections is flexible and complex, as they might
be comprised of different major genotypes or subtypes.
The prevalence of mixed HCV genotype infections is also
difficult to ascertain, with ranges from 0% to 25% having
been reported depending on the genotyping method, defi-
nition of mixed infection, and study population [29e37].
The presence of mixed infections has been proposed as a
potential cause for poor response to interferon-based
antiviral therapy, as selection of minority genotype pop-
ulations more refractory to antiviral treatment can occur
during treatment [38]. The precision of studies on the
transmission of HCV also depends on whether coexisting
genotypes can be tracked along with the other ones. In the
current study, we investigated patients with mixed in-
fections of HCV-1 and HCV-2 for two reasons: first, they IL-28B genotype.
7 TT genotype Rs8099917 non-TT genotype p
0 (0.94) * 5.53 (0.70) 0.87
0 (0.83) 5.55 (0.74) 0.84
6 (0.97) * 5.51 (0.70) 0.80
9 (1.02) * 5.57 (0.54) 0.003
/2 Z HCV genotype 1 and HCV genotype 2 mixed infection;
Figure 2. Percentage of patients with high HCV RNA levels
between patients with mixed HCV-1/2 and HCV-2 infection.
The black bar represents patients with mixed HCV-1/2 infec-
tion. The white bar represents patients with HCV-2 infection.
HCVZ hepatitis C virus; HVLZ high viral loads, defined as HCV
RNA levels >400,000 IU/mL.
276 C.-F. Huang et al.patients might be frequently encountered in daily practice
in countries where both HCV genotypes prevail. Second,
treatment strategies toward the two genotypes are largely
different. It is therefore more rational and very essential to
explore the characteristics of the virus and patients before
we can fully address the treatment efficacy in this specific
population.
It has been suggested that patients infected with HCV-1
have higher HCV RNA levels compared with patients with
HCV-2 infection [39]. Intriguingly, we demonstrated that
patients with mixed HCV-1/2 infection had similar HCV RNA
levels to patients with nonmixed HCV-1 but significantly
higher HCV RNA levels than those with HCV-2 infection.
Higher body weight was also independently associated with
high viral loads. The precise reason was uncertain. Meta-
bolic disarrangement in terms of insulin resistance and lipid
disorders have been associated with HCV viral loads [39],
which might be partially responsible for the result.
Host IL-28B genetic variants are currently the most
important host factor in determining viral eradication
either by antiviral therapy [10e14] or self-limited HCV
infection [15]. The distribution of IL-28B genetic variants
would account for diverse treatment outcomes not only
across different ethnicities of patients but also different
viral genotypes [16]. We have previously demonstrated that
the favorable IL-28B rs8099917 TT genotype was over-
represented among HCV-non-1 infected patients, compared
with HCV-1 patients (91.4% vs. 85.0%, p Z 0.002) [16]. In
the current study, we noticed that IL-28B genetic distri-
bution in patients with mixed HCV-1/2 infection was more
similar to patients with HCV-1 infection, with a lower pro-
portion of favorable genotype carriage. Further studies to
explore the treatment efficacy of the population based on
these findings are warranted.
Although patients were stratified according to IL-28B
genotype, lower HCV RNA levels were only noted in HCV-2
patients with the favorable rs8099917 TT genotype. It has
been suggested that HCV-1 patients with a favorable IL-28B
genotype have higher HCV RNA levels [12], which might
attribute to viral selection during evolution. However, theresults were not consistent across all studies with different
HCV genotypes [22,40]. The conflicting finding might in part
result from selection bias of hospital-based studies. Further
community-based studies enrolling larger sample size might
be needed before a definite conclusion of the issue could be
made.
The limitation of the current study was that we failed to
determine the predominant viral genotype in a given pa-
tient. To address this issue, a detailed cloning or deep
sequence analysis might provide more precise evaluation.
However, it is complicated and time-consuming and
therefore is difficult to be applied to large-scale studies.
Since the acquisition of HCV is frequently asymptomatic,
we failed to judge the impact of duration of infection on
liver fibrosis among study groups. The viral interference of
heterologous HCV genotypes in the same host might be
dynamic during the course of superinfection [18,28]. How-
ever, patients selected in the current hospital cohort were
chronically infected and had been scheduled to receive
antiviral therapy, so the viral presentation of mixed HCV1/2
infection in the same host was consistent in the current
patient cohort.
In conclusion, patients with mixed HCV-1/2 infection are
frequently encountered in Taiwan. This should also be the
case in areas where both viral genotypes are endemic. Both
the viral and host genetic features in patients with mixed
HCV-1/2 infection were more similar to those with HCV-1
infection than those with HCV-2 infection. In the era of
direct antiviral agents (DAAs), so far, there is no solution for
how to manage this specific population, unless pan-
genotypic DAAs are made widely available. The current
study might provide insight and further guidance regarding
the treatment of patients with mixed infections of HCV-1
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